A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT01801163 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Trial had no patients accrued while open

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Sorafenib
RADIATION: Stereotactic radiotherapy

Sponsor

Indiana University